Literature DB >> 18594968

Expression and prognostic value of ZNRD1 in esophageal squamous cell carcinoma.

Yunping Zhao1, Liu Hong, Ruwen Wang, Daiming Fan.   

Abstract

The expression of ZNRD1 in esophageal cancer was first investigated by immunohistochemical analysis, RT-PCR and real-time PCR. The ZNRD1 antibody produced a consistently cytoplasmic staining pattern in all epithelial cells. The expression of ZNRD1 was statistically correlated with differentiation, depth of invasion, lymph node metastasis, pathological stage, lymphatic invasion, and vascular invasion. The survival rates of patients with ZNRD1-negative tumors tended to be statistically lower than those with ZNRD1-positive tumors. ZNRD1 expression was also confirmed to be down-regulated in esophageal cancer tissues compared to adjacent non-neoplastic tissues. The results showed that ZNRD1 might play an important role in esophageal carcinogenesis.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18594968     DOI： 10.1007/s10620-008-0380-1

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


  19 in total

1.  ZNRD1 gene suppresses cell proliferation through cell cycle arrest in G1 phase.

Authors:  Liu Hong; Yu Han; Rui Shi; Xiaodong Shao; Lijun Sun; Yumei Zhang; Dawei Huang; Zhen Chen; Guoyun Zhang; Jie Liang; Shengjuan Hu; Daiming Fan
Journal:  Cancer Biol Ther       Date:  2005-01-15       Impact factor: 4.742

Review 2.  Distinctive clinicopathological characteristics in esophageal squamous cell carcinoma.

Authors:  Hiroyuki Kuwano; Masanobu Nakajima; Tatsuya Miyazaki; Hiroyuki Kato
Journal:  Ann Thorac Cardiovasc Surg       Date:  2003-02       Impact factor: 1.520

3.  ZNRD1 mediates resistance of gastric cancer cells to methotrexate by regulation of IMPDH2 and Bcl-2.

Authors:  Liu Hong; Taidong Qiao; Yu Han; Shuang Han; Xiaoyin Zhang; Tao Lin; Juan Gao; Pengtao Zhao; Zhen Chen; Daiming Fan
Journal:  Biochem Cell Biol       Date:  2006-04       Impact factor: 3.626

4.  The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas.

Authors:  Björn L D M Brücher; Karen Becker; Florian Lordick; Ulrich Fink; Mario Sarbia; Hubert Stein; Raymonde Busch; Frank Zimmermann; Michael Molls; Heinz Höfler; Jörg R Siewert
Journal:  Cancer       Date:  2006-05-15       Impact factor: 6.860

Review 5.  Novel targeted therapies in the treatment of gastric and esophageal cancer.

Authors:  J Tabernero; T Macarulla; F J Ramos; J Baselga
Journal:  Ann Oncol       Date:  2005-06-24       Impact factor: 32.976

6.  Reversal of multidrug resistance of gastric cancer cells by down-regulation of ZNRD1 with ZNRD1 siRNA.

Authors:  L Hong; X Ning; Y Shi; H Shen; Y Zhang; M Lan; S Liang; J Wang; D Fan
Journal:  Br J Biomed Sci       Date:  2004       Impact factor: 3.829

7.  Suppression of the cell proliferation in stomach cancer cells by the ZNRD1 gene.

Authors:  Liu Hong; Yumei Zhang; Na Liu; Changjiang Liu; Min Zhi; Yanglin Pan; Mei Lan; Li Sun; Daiming Fan
Journal:  Biochem Biophys Res Commun       Date:  2004-08-27       Impact factor: 3.575

8.  Reversal of multidrug resistance of adriamycin-resistant gastric adenocarcinoma cells through the up-regulation of DARPP-32.

Authors:  Liu Hong; Yunping Zhao; Jin Wang; Ying Han; Wei Guo; Haifeng Jin; Huihong Zhai; Feihu Bai; Xiaoyin Zhang; Taidong Qiao; Zhen Chen; Daiming Fan
Journal:  Dig Dis Sci       Date:  2007-05-11       Impact factor: 3.199

Review 9.  Zinc ribbon domain containing 1 protein: modulator of multidrug resistance, tumorigenesis and cell cycle.

Authors:  L Hong; Z Chen; X Zhang; L Xia; Z Han; Y Lu; H Jin; J Song; T Qiao; D Fan
Journal:  Exp Oncol       Date:  2006-12

10.  Significant host- and tumor-related factors for predicting prognosis in patients with esophageal carcinoma.

Authors:  Masanori Ikeda; Shoji Natsugoe; Shinichi Ueno; Masamichi Baba; Takashi Aikou
Journal:  Ann Surg       Date:  2003-08       Impact factor: 12.969
View more
  4 in total

1.  Strong evidence for LncRNA ZNRD1-AS1, and its functional Cis- eQTL locus contributing more to the susceptibility of lung cancer.

Authors:  Dan Li; Lei Song; Zhongmei Wen; Xiaoping Li; Jing Jie; Yan Wang; Liping Peng
Journal:  Oncotarget       Date:  2016-06-14

2.  MiR-26b suppresses hepatocellular carcinoma development by negatively regulating ZNRD1 and Wnt/β-catenin signaling.

Authors:  Xiaobo Hu; Ruifang Wang; Zhigang Ren; Xiaorui Liu; Junsheng Gu; Guangying Cui; Qinggang Li
Journal:  Cancer Med       Date:  2019-10-21       Impact factor: 4.452

3.  ZNRD1 and Its Antisense Long Noncoding RNA ZNRD1-AS1 Are Oppositely Regulated by Cold Atmospheric Plasma in Breast Cancer Cells.

Authors:  Hyeon Woo Kim; Dawoon Jeong; Juyeon Ham; Heejoo Kim; Hwee Won Ji; Eun Ha Choi; Sun Jung Kim
Journal:  Oxid Med Cell Longev       Date:  2020-05-05       Impact factor: 6.543

4.  ZNRD1-AS1 Promotes Nasopharyngeal Carcinoma Cell Invasion and Metastasis by Regulating the miR-335-ROCK1 Axis.

Authors:  Qiang Wang; Xinyu Hu; Mingyu Du; Zhiwei Lu; Keshi Yan; Dingliang Zhao; Ning Jiang; Yi Peng; Xia He; Li Yin
Journal:  Onco Targets Ther       Date:  2020-05-27       Impact factor: 4.147
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.